Search results
Results from the WOW.Com Content Network
One study with lab rats published in 2009 concluded that some of the possible risks of pancreatitis or pancreatic cancer may be reduced when it is used with metformin. However, while DPP-4 inhibitors showed an increase in such risk factors, as of 2009, no increase in pancreatic cancer has been reported in individuals taking DPP-4 inhibitors. [26]
A 2014 review found increased risk of heart failure with saxagliptin and alogliptin, prompting the FDA in 2016 to add warnings to the relevant drug labels. [22] A 2018 meta analysis showed that use of DPP-4 inhibitors was associated with a 58% increased risk of developing acute pancreatitis compared with placebo or no treatment. [23]
Smoking increases the risk of both acute and chronic pancreatitis. [3] [4] Diagnosis of acute pancreatitis is based on a threefold increase in the blood of either amylase or lipase. [1] In chronic pancreatitis, these tests may be normal. [1] Medical imaging such as ultrasound and CT scan may also be useful. [1]
The Food and Drug Administration warned Thursday that diabetes drugs might be elevating the rate of pancreatic cancer. Investors shouldn't be surprised. Nor particularly worried. We've known for ...
Diabetes drug Januvia has been a boon for Merck in recent years, and its massive year-over-year growth was one way the company was able to offset the huge losses incurred by Singulair's recent ...
For the last several years, Merck has been able to ride the success of its leading type 2 diabetes franchise Januvia/Janumet, which generated $5.75 billion in sales last year and represented more ...
In the United States, sitagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. [5] [6]In the European Union, sitagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in people with type 2 diabetes; in combination with a sulfonylurea as an adjunct to diet and exercise "in people ...
Exocrine pancreatic insufficiency (EPI) is the inability to properly digest food due to a lack or reduction of digestive enzymes made by the pancreas.EPI can occur in humans and is prevalent in many conditions [1] such as cystic fibrosis, [2] Shwachman–Diamond syndrome, [3] different types of pancreatitis, [4] multiple types of diabetes mellitus (Type 1 and Type 2 diabetes), [5] advanced ...